← Back to Search

Electrocorticography for Brain Tumor

N/A

Recruiting

Led By Sujit S Prabhu

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients aged 18 years and above

Patients undergoing a tumor resection at the University of Texas M. D. Anderson Cancer Center for a newly diagnosed as well as recurrent primary or metastatic brain tumor located in or adjacent to motor and/or speech brain areas

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months (± 4 weeks)

Awards & highlights

No Placebo-Only Group

Summary

This trial studies how well a larger than standard mapping grid works in identifying functional areas of the brain during surgery in patients with brain tumors.

Who is the study for?

This trial is for adults with new or recurring primary or metastatic brain tumors near motor/speech areas, who are undergoing tumor resection at the University of Texas M. D. Anderson Cancer Center. Participants must be able to perform tasks during awake surgery and have signed consent. Those with significant upper limb or speech deficits, impaired vision/hearing affecting study participation are excluded.

What is being tested?

The trial tests electrocorticography (ECoG) using a standard or high-definition grid to map active brain regions during surgery in patients with brain tumors. It aims to improve identification of functional areas related to limb movement and speech.

What are the potential side effects?

As this is a diagnostic procedure rather than a drug treatment, side effects may include typical surgical risks such as infection, bleeding, and potential neurological changes due to the mapping process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I am having surgery at M.D. Anderson for a brain tumor near speech or motor areas.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months (± 4 weeks)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months (± 4 weeks)

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months (± 4 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Electrocorticogram (ECoG)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (electrocorticography)Experimental Treatment2 Interventions

Patients undergo tumor resection. During surgery, patients also undergo electrocorticography with either the CorTec high resolution hybrid grid, the PMT high-resolution grid, or the Ad-Tech grid followed by direct electrocortical stimulation.

0 / 2Eligibility criteria met